PubMed · 11633657
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
1990. [Not Available].. https://pubmed.ncbi.nlm.nih.gov/11633657/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
BACKGROUND AND OBJECTIVE: Successful laser treatment of port wine stain (PWS) birthmarks requires knowledge of lesion geometry. Laser parameters, such as pulse duration, wavelength, and radiant exposure, and other treatment parameters, such as cryogen spurt duration, need to be optimized according to epidermal melanin content and lesion depth. We designed, constructed, and clinically tested a photoacoustic probe for PWS depth determination. STUDY DESIGN/MATERIALS AND METHODS: Energy from a frequency-doubled, Nd:YAG laser (lambda=532 nm, tau(p)=4 nanoseconds) was coupled into two 1,500 mum optical fibers fitted into an acrylic handpiece containing a piezoelectric acoustic detector. Laser light induced photoacoustic waves in tissue phantoms and a patient's PWS. The photoacoustic propagation time was used to calculate the depth of the embedded absorbers and PWS lesion. RESULTS: Calculated chromophore depths in tissue phantoms were within 10% of the actual depths of the phantoms. PWS depths were calculated as the sum of the epidermal thickness, determined by optical coherence tomography (OCT), and the epidermal-to-PWS thickness, determined photoacoustically. PWS depths were all in the range of 310-570 microm. The experimentally determined PWS depths were within 20% of those measured by optical Doppler tomography (ODT). CONCLUSIONS: PWS lesion depth can be determined by a photoacoustic method that utilizes acoustic propagation time.
Novel therapies for dermatologic diseases are now widely available to the clinician. The topical immune modulators tacrolimus and pimecrolimus are likely to change the way in which inflammatory dermatoses are treated. Antiviral and antitumor effects of imiquimod, another immune-response modifier, are being studied to determine the ways in which it may affect the treatment of cutaneous viral infections and skin cancers. New topical treatments for onychomycosis and the current lack of effective treatments for nondermatophyte onychomycosis indicate the need for more effective treatment for this common disease. Exciting developments in skin substitutes and growth factors for acute and chronic wound care hold much promise for the future.